KBC Group NV Has $35,000 Stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

KBC Group NV increased its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 59.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,593 shares of the biotechnology company’s stock after purchasing an additional 3,198 shares during the quarter. KBC Group NV’s holdings in Ironwood Pharmaceuticals were worth $35,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in shares of Ironwood Pharmaceuticals by 21.8% in the 1st quarter. Vanguard Group Inc. now owns 19,521,366 shares of the biotechnology company’s stock valued at $170,031,000 after buying an additional 3,487,821 shares in the last quarter. Armistice Capital LLC increased its stake in Ironwood Pharmaceuticals by 44.4% in the second quarter. Armistice Capital LLC now owns 7,800,000 shares of the biotechnology company’s stock valued at $50,856,000 after acquiring an additional 2,400,000 shares during the period. Pacer Advisors Inc. raised its position in Ironwood Pharmaceuticals by 23.6% in the second quarter. Pacer Advisors Inc. now owns 8,907,639 shares of the biotechnology company’s stock worth $58,078,000 after purchasing an additional 1,701,452 shares in the last quarter. Kynam Capital Management LP bought a new position in Ironwood Pharmaceuticals during the first quarter worth about $14,154,000. Finally, Renaissance Technologies LLC boosted its holdings in Ironwood Pharmaceuticals by 20.7% during the second quarter. Renaissance Technologies LLC now owns 8,571,898 shares of the biotechnology company’s stock valued at $55,889,000 after purchasing an additional 1,472,097 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on IRWD. Capital One Financial cut Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $12.00 to $4.00 in a report on Thursday, August 8th. StockNews.com cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Wells Fargo & Company lowered their target price on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, August 9th. Craig Hallum cut their price target on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 9th. Finally, Leerink Partnrs raised shares of Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $10.40.

Ironwood Pharmaceuticals Stock Up 3.0 %

Ironwood Pharmaceuticals stock opened at $3.44 on Friday. The stock has a 50-day simple moving average of $4.21 and a 200 day simple moving average of $5.33. The stock has a market capitalization of $550.50 million, a price-to-earnings ratio of -114.67 and a beta of 0.47. Ironwood Pharmaceuticals, Inc. has a 12-month low of $3.26 and a 12-month high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The company had revenue of $91.60 million for the quarter, compared to analyst estimates of $91.22 million. During the same quarter in the previous year, the company posted $0.12 earnings per share. Ironwood Pharmaceuticals’s revenue for the quarter was down 19.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Sravan Kumar Emany sold 11,001 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.08, for a total value of $44,884.08. Following the completion of the sale, the chief financial officer now directly owns 309,572 shares in the company, valued at $1,263,053.76. This trade represents a 3.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 12.90% of the company’s stock.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.